Browse Programs  /  Benefits of Screening for Early Type 1 Diabetes

Benefits of Screening for Early Type 1 Diabetes



When This ECHO Meets

This series will be held on Thursdays from 12:00 - 1:00 PM MT for 4 weeks

What This ECHO Will Focus On

The goal of this series is to increase awareness of the indications and expected outcomes of Tzield (teplizumab) while emphasizing the importance of early screening for type 1 diabetes (T1D) associated autoantibodies, particularly in individuals with heightened familial risk-factors. The four-session series will explain the benefits and risks of screening for early T1D and summarize how appropriate follow up of a person who screens positive for early T1D is essential to preventing diabetic ketoacidosis at disease onset. Additionally, discussion will occur on which stages of T1D have FDA-approved treatment options other than insulin as well as listing the clinical treatment options for patients with early T1D. Learn from experts in the field on how to incorporate these tools into your practice in order to gain confidence and improve care for your patients.  

Learning Objectives/Outcomes

  • Define the scope of screening for early type one diabetes (T1D), including who to screen, when screening is most beneficial, how to screen and programs for screening.
  • Discuss how patients who are screened and confirmed positive for T1D should be managed in clinic, including symptom education, self-blood glucose monitoring education, HbA1c measurement, oral glucose tolerance tests (OGTT), continuous glucose monitoring (CGM) and behavioral health support at regular intervals.
  • Summarize how appropriate follow up of these patients can be done in collaboration with the Barbara Davis Center for Diabetes (BDC) Early T1D clinic or a BDC clinical research program.
  • Discuss resources that are available for patients who screen positive for T1D.
  • Discuss resources that are available for primary care or pediatric physicians, including the BDC clinic, Ask the Experts and e-consults for asynchronous and collaborative patient care.

Start Date

April 11, 2024


End Date

May 2, 2024

Session/Title
Date
Time